Clinical Trials Browser

INDUSTRY × Prostatic Neoplasms × siltuximab × Clear all

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase 2 Terminated

106 enrolled 13 charts

Neoplasms, Prostatic Neoplasms

NCT00401765 2014-05-26

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms